ArticleFrontiers in public health2026
Association of biological age acceleration with cardiovascular disease and premature mortality: a population-based prospective cohort study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accelerated biological ageing is associated with age-related diseases, but sex differences in its association with cardiovascular disease (CVD) and premature mortality remain largely unknown. We aimed to assess the associations between biological age (BA) acceleration and CVD, premature mortality, and examine potential sex differences. Methods: This population-based prospective cohort study included participants aged 39 to 71 years from UK Biobank study, recruited between 2006 and 2010, and followed up until Dec 20, 2022. BA, derived from clinical biomarkers, was calculated using the Klemera-Doubal method (KDM-BA) and PhenoAge algorithms. BA acceleration was defined as the residual from regressing BA based on chronological age. Incident CVD and premature mortality (defined as death before age 70) were identified using ICD-9 and ICD-10 codes. Multivariable-adjusted Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) across BA acceleration quartiles. Results: Among 122,133 participants who were free of CVD at baseline (mean [SD] age, 56.0 [8.1] years; 65,442 [53.6%] women), 24,281 incident CVD cases and 3,614 premature deaths were reported. Restricted cubic splines showed progressively increasing risks of incident CVD and premature mortality associated with higher BA acceleration. Compared with the lowest quartile of KDM-BA acceleration, the largest adjusted HRs for incident CVD and premature mortality were 1.32 (95% CI 1.27-1.37) and 1.10 (95% CI 1.05-1.21) for quartile 4, respectively. For PhenoAge acceleration, the corresponding HRs were 1.23 (95% CI 1.19-1.28) and 1.21 (95% CI 1.10-1.33), respectively. These associations were more pronounced among male participants ( Discussion: In this cohort study, higher BA acceleration was associated with increased risks of incident CVD and premature mortality, with more pronounced association observed in males. These findings suggest the need to exploring BA acceleration as a modifiable risk factor to optimize risk assessment, and to implement sex-specific strategies to improve health outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.